Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

cinepazide

Known as: 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
This study aims to explore and analyze the condition of concurrent diseases and medicine use of traditional Chinese medicine (TCM… Expand
2013
2013
Background and ObjectiveMildronate, an inhibitor of carnitine-dependent metabolism, is considered to be an anti-ischemic drug… Expand
  • figure 1
  • table 1
  • table 2
Highly Cited
2005
Highly Cited
2005
BACKGROUND Since the publication of a major international case-control study on the risk of agranulocytosis associated with the… Expand
  • figure I
  • table 1
  • table 2
Highly Cited
1991
Highly Cited
1991
The risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs were estimated in a population… Expand
1988
1988
We studied the effects of a series of 16 vasodilators on the intrahepatic vasoconstriction induced by norepinephrine in the… Expand
1984
1984
The effects of cinepazide, 1-[(1-pyrrolidinylcarbonyl)methyl]-4-(3,4,5-trimethoxycinnamoyl )piperazine hydrogen maleate, were… Expand
1980
1980
Physical dependence liability to cinepazide was studied, and the following were found : 1. Rats were applied cinepazide for 96… Expand
1980
1980
The negative inotropic effects of adenosine and adenine nucleotides, such as ATP and cAMP, on guinea-pig atria were selectively… Expand
1979
1979
Cardiovascular effects of cinepazide were compared with those of cinnarizine and papaverine. Cinepazide (3-30 mg/kg, i.v… Expand
1976
1976
1. An oral dose of the coronary vasodilator 4-(3,4,5-trimethoxy[14C]cinnamoyl)-1-(N-pyrrolidinocarbonylmethyl)piperazine was well… Expand